 |
|
For further information please contact: UNITECH Communications 216-448-0770 800-238-6750
|
 |
The Cleveland Clinic Foundation Center for Continuing Education acknowledges Bronze Roche Salix Pharmaceuticals Other Contributors Covidien Ocera Therapeutics Valeant Pharmaceuticals International
The Cleveland Clinic Foundation Center for Continuing Education acknowledges Bristol-Myers Squibb Gilead Sciences, Inc. |
Seventh Annual Liver Update 2008
A Report from the American Association for the Study of
Liver Diseases Annual Meeting
December 6, 2008
Cleveland Clinic Administrative Campus, AC3 Auditorium
3050 Science Park Drive
Beachwood, Ohio
 |
|||
 |
For the complete brochure click here (211 KB) |
 |
|
|
|||
Please join us for the Cleveland Clinic 7th Annual Liver Update: A Report from AASLD on Saturday, December 6, 2008, at the Cleveland Clinic Administrative Campus in Beachwood, Ohio. Many of you know the Annual Liver Update as a vibrant report of key abstracts from the annual AASLD meeting, which will be held in San Francisco this year.
In response to many requests, we have moved the Liver Update to Saturday morning. This enables us to expand the format and to devote more time to the excellent clinical research reports presented at AASLD. These reviews will focus on new developments in the area of GI bleeding, hepatic encephalopathy, hepatitis B and C, cholestatic liver disease, metabolic and fatty liver disease, liver cancer, and liver transplantation.
After our traditional meeting, we will present an optional session on hepatitis B titled, B-SMART: Hepatitis B. This session will bring together thought leaders from around the country to discuss topics on the natural history of hepatitis B, its effect on special population groups, and provide an update on treatment options.
At the conclusion of this course, participants will be able to:
- Describe the most important research findings as they apply to clinical practice and relate their effect on established practice guidelines;
- Identify optimal treatment strategies for liver disease and related complications based on the most recent clinical trial data;
- Compare new therapeutic modalities;
- Select the most effective screening and monitoring strategies;
- Describe action plans for physicians to overcome barriers to the identification and treatment of hepatitis B in immigrant poplulations;
- Compare and contrast therapeutic profiles for drug classes approved to treat hepatitis B, including data on combination therapies.
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Liver Update: Maximum 3.0 AMA PRA Category 1 Credit(s)TM
Optional Session – B-SMART: Hepatitis B: Maximum 2.0 AMA PRA Category 1 Credit(s)TM.
This activity may be submitted for American Osteopathic
Association Continuing Medical Education credit in
Category 2.
This course uses our online registration system which instantly issues you a receipt immediately.
Instructions for first time users:
- Login initially by selecting a registration category (Physician, Nurses, etc) from the drop down menu.
- Provide your personal information (name, address, telephone, and a 4 digit number password of your choice). The password is required and will serve as your login identification for all future registrations.
- Select course options and enter payment information in the next screen.
| Category | Fee |
| Attendees | complimentary |